Home » ENZYMOTEC AND IL DONG TO COLLABORATE ON CVD TREATMENT
ENZYMOTEC AND IL DONG TO COLLABORATE ON CVD TREATMENT
Israeli biotech company Enzymotec and Korean pharmaceuticals manufacturer Il Dong have signed an agreement to launch a treatment for cardiovascular disease (CVD) in the Korean market.
The new product, CardiaBeat, based on Enzymotec's clinical trials, enhances
the impact of phytosterols and omega-3 fatty acids for reducing the risk for
cardiovascular disease. Enzymotec and Il Dong intend to develop additional products
for the Korean market, focusing on cardiovascular solutions.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct